A pulse pressure (PP) below 35-40 mm Hg has been shown to carry a worse prognosis in patients with chronic heart failure (CHF), but its non-dependence on peak oxygen uptake, which is a major if not the major prognostic factor in these patients, has not been studied. We assessed whether PP adds prognostic precision to peak oxygen uptake in 284 patients with advanced CHF, in whom blood pressure (BP) was measured at rest and who performed a graded symptom-limited bicycle exercise test with respiratory gas analysis. The results confirm that a low PP rather than a high PP predicts cardiovascular (CV) mortality in patients with CHF and that PP adds prognostic value to peak oxygen uptake, which is the strongest predictor of outcome.
Pulse pressure (PP) is determined by vascular stiffness and by left ventricular (LV) ejection rate or stroke volume. In the population at large and in patients with hypertension without clinical evidence of LV dysfunction, PP mainly reflects vascular stiffness, which explains the association of a high PP with a worse prognosis. [1] [2] [3] [4] By contrast, recent studies have shown that a low PP carries a worse prognosis in patients with advanced chronic heart failure (CHF) 5, 6 and decompensated heart failure, 7 which is attributed to the fact that the impaired LV function has become the major determinant of PP. However, peak oxygen uptake (VO 2 peak), which is a major if not the major prognostic factor in CHF 8, 9 was not considered in these studies. Our aim was therefore to analyse whether PP adds prognostic precision to VO 2 peak in patients with advanced CHF, who were referred to our centre for assessment of their suitability for heart transplantation (HTX) between May 1991 and December 1996 and who performed a graded symptom-limited bicycle exercise test with measurement of respiratory gas analysis, including VO 2 peak. 9 Blood pressure (BP) was measured by the auscultatory technique using the STBP-78 device (Colin, Komaki, Japan) or directly by trained investigators, at rest in the sitting position before the exercise test. PP was calculated as the difference between systolic and diastolic BP, and mean BP as diastolic BP plus one-third of PP.
Information on vital status and cause of death, starting on the date of the exercise test till the end of 1997, was obtained in all patients from hospital files and the patient's physician(s).
We used multivariable regression analysis to define the determinants of PP and the Cox proportional hazards regression model for survival analysis.
We examined whether the baseline data were predictive for the time to death from a cardiovascular (CV) cause. Patients who underwent HTX during follow-up were censored at the time of HTX. Survival analyses were also performed with exclusion of these patients. The prognostic value of a variable is given by its hazard ratio (HR), which estimates how much the incidence of the event changes when the independent variable increases by a predefined amount or whether it is present or not. The following variables were considered as possible determinants of CV mortality: VO 2 peak, PP, mean, systolic and diastolic BP, heart rate, age, gender, body mass index, LVEF, CHF aetiology, history of hypertension or diabetes, and serum sodium and creatinine concentration. Table 1 summarizes the general characteristics of the 284 patients. Median PP was 40 mm Hg (range: 12-82 mm Hg). During follow-up, 102 or 36% of the patients underwent HTX. Median time of follow-up (time until death, HTX, or the last available information on vital status) was 1.33 years (range: 9 days-6.01 years). During the total follow-up time of 523 patient-years, 54 patients died from a CV cause (sudden death: 26; heart failure: 21; arrhythmias: 6; stroke: 1), at a median age of 59.5 years (range: 24-69 years). Three patients died from a noncardiovascular cause (two patients from cancer and one from bronchopulmonary infection).
In multivariable regression analysis, PP was significantly and positively related to mean BP and to left ventricular ejection fraction (LVEF) and negatively to heart rate. Regression coefficients (7s.e.) were, respectively, þ 0.3970.061 mm Hg per mm Hg for mean BP; þ 0.2770.060 mm Hg per 1% for LVEF; and À0.2270.053 mm Hg per 1 b.p.m. for heart rate (Po0.001 for all). These three variables explained 28% of the variance of PP.
PP was not a significant independent predictor of CV mortality when offered as a continuous variable to the multivariable Cox regression model. Only VO 2 peak and serum sodium concentration were significant and independent predictors: a 1 ml/kg/ min higher VO 2 peak was associated with a 10% lower CV mortality (HR: 0.90; 95% confidence interval (CI): 0.84-0.96; P ¼ 0.002) and a 1 mmol/l higher serum sodium concentration was associated with a 7% lower mortality (HR: 0.93; 95% CI: 0.87-1.00; P ¼ 0.04). When PP was offered as a dichotomous variable, VO 2 peak remained the strongest predictor of CV mortality (HR: 0.89; 95% CI: 0.84-0.95; Po0.001) and, in addition, patients with PP greater than the median value of 40 mm Hg had a 47% lower risk than that when PP was p40 mm Hg (HR: 0.53; 95% CI: 0.29-0.93; P ¼ 0.03). The results were similar when the 102 patients who underwent HTX were excluded from the analyses.
The present study confirms that a low PP rather than a high PP predicts CV mortality in patients with advanced CHF and shows that PP adds prognostic value to VO 2 peak, which is the strongest predictor of outcome. Two comments are of interest. First, when the current and previous studies are considered together it appears that the impaired prognosis is mainly associated with PP o35-40 mm Hg and that outcome is rather similar in subgroups with PP above that level. [5] [6] [7] Second, a low PP is associated with a worse outcome in patients with CHF, whereas the inverse is true in other patient populations, that is hypertensive patients, 1, 3, 4 survivors of myocardial infarction 10 and even patients with LV dysfunction or mild heart failure. 11 This can be explained by the fact that PP results from vascular stiffening and ejection rate or stroke volume. In the absence of advanced CHF, a high PP mainly reflects vascular stiffening, which contributes to a worse prognosis, whereas in patients with advanced CHF, LV ejection rate is the main determinant of PP so that a low PP reflects at least partly poor LV function and a worse prognosis. It has been shown in univariable regression analysis that LVEF is a significant determinant of PP. 10, 11 In the current study, we observed that this relationship was independent of a number of potential confounders, as also reported by Tartière et al.
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A number of limitations have to be considered. We used an existing database 9 to assess the prognostic significance of a low PP in patients with advanced CHF, mainly to determine whether PP adds prognostic precision to the generally accepted prognostic value of VO 2 peak. 8, 9 Drug treatment for CHF was based on ACE inhibitors, diuretics and digoxin, which is compatible with common practice at the time of the study. b-blockers and mineralocorticoid receptor blockers were not systematically used in our patients because convincing evidence from randomized controlled trials of beneficial effects of these drugs on survival only became available by the end (b-blockers) or after the end (spironolactone) of the current study. Our study involved patients who were referred to assess their suitability for HTX, but who were still able to perform a maximal/symptom-limited exercise test. Our findings can therefore not be extrapolated to other patients with CHF. It is possible that the prognostic value of PP is of particular importance in patients with severe CHF who are unable to exercise. Measurements of vascular stiffness, such as pulse wave velocity and carotid augmentation index, were not included in the pre-HTX evaluation of our patients, so that we could not include an independent assessment of vascular stiffness in the analyses. Finally, the size of our single-centre study is relatively small and confirmation of our results in larger studies is warranted.
In conclusion, a low PP rather than a high PP carries a worse prognosis in patients with advanced CHF. However, in CHF patients able to perform a maximal/symptom-limited exercise test, VO 2 peak is the most powerful prognostic factor; but, for a particular value of VO 2 peak, an unfavourable outcome can be expected when PP is p40 mm Hg. What is known about the topic K A low-pulse pressure is associated with a worse prognosis in patients with chronic heart failure.
5-7
K Peak oxygen uptake is a major prognostic factor in patients with chronic heart failure.
8À9
K It is not known if the prognostic significance of pulse pressure is independent of peak oxygen uptake.
What this study adds K Peak oxygen uptake is a strong predictor of cardiovascular mortality in heart transplant candidates. K For a particular value of peak oxygen uptake, an unfavourable outcome can be expected in patients with pulse pressurep40 mm Hg.
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